Description

OPKO Health, Inc. is an international healthcare enterprise primarily operating across two core divisions: diagnostics and pharmaceuticals. Its global footprint extends across the United States, Ireland, Chile, Spain, Israel, Mexico, and various other international regions. Within its Diagnostics segment, the company manages BioReference Laboratories, which furnishes a comprehensive suite of laboratory testing services. These services are crucial for the identification, diagnosis, assessment, monitoring, and management of various diseases, encompassing specialized esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health services, and correctional healthcare. BioReference caters to a diverse clientele, including physicians' offices, medical clinics, hospitals, employers, and governmental organizations. This segment also provides a cutting-edge diagnostic instrument system designed to deliver rapid blood test results at the point of care, alongside specialized 4Kscore prostate cancer testing. The Pharmaceutical division focuses on the development and commercialization of therapeutic products. Its flagship offering, Rayaldee, is prescribed to adults grappling with secondary hyperparathyroidism linked to stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline includes OPK88004, an orally administered selective androgen receptor modulator, and OPK88003, a once-weekly peptide undergoing Phase IIb trials for the treatment of type 2 diabetes and associated obesity. Furthermore, in collaboration with Pfizer, Inc., the company completed Phase III clinical trials for hGH-CTP, a human growth hormone administered once weekly. This segment's strategy involves creating and commercializing proprietary, longer-acting iterations of established therapeutic proteins. Beyond these, the company is actively involved in developing, manufacturing, marketing, and distributing a broad array of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. This includes the commercialization of food supplements and over-the-counter medicines, production and sales within the generics market, and the import, marketing, distribution, and sale of pharmaceutical products for a wide range of indications such as cardiovascular health, vaccines, antibiotics, gastrointestinal issues, and hormonal conditions. Pharmaceutical platforms are maintained in Ireland, Chile, Spain, and Mexico. Established in 1991, OPKO Health maintains its corporate headquarters in Miami, Florida.